share_log

Earnings Miss: Angel Yeast Co., Ltd Missed EPS By 8.0% And Analysts Are Revising Their Forecasts

Simply Wall St ·  Mar 20 20:25

As you might know, Angel Yeast Co., Ltd (SHSE:600298) last week released its latest yearly, and things did not turn out so great for shareholders. Angel Yeast missed analyst forecasts, with revenues of CN¥14b and statutory earnings per share (EPS) of CN¥1.47, falling short by 3.3% and 8.0% respectively. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

earnings-and-revenue-growth
SHSE:600298 Earnings and Revenue Growth March 21st 2024

Taking into account the latest results, the most recent consensus for Angel Yeast from 15 analysts is for revenues of CN¥15.4b in 2024. If met, it would imply a decent 13% increase on its revenue over the past 12 months. Per-share earnings are expected to bounce 23% to CN¥1.79. Yet prior to the latest earnings, the analysts had been anticipated revenues of CN¥15.9b and earnings per share (EPS) of CN¥1.91 in 2024. The analysts are less bullish than they were before these results, given the reduced revenue forecasts and the small dip in earnings per share expectations.

The consensus price target fell 7.2% to CN¥38.18, with the weaker earnings outlook clearly leading valuation estimates. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Angel Yeast analyst has a price target of CN¥48.00 per share, while the most pessimistic values it at CN¥26.40. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Angel Yeast shareholders.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2024 brings more of the same, according to the analysts, with revenue forecast to display 13% growth on an annualised basis. That is in line with its 15% annual growth over the past five years. Juxtapose this against our data, which suggests that other companies (with analyst coverage) in the industry are forecast to see their revenues grow 13% per year. So although Angel Yeast is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Sadly, they also downgraded their revenue forecasts, but the business is still expected to grow at roughly the same rate as the industry itself. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Angel Yeast's future valuation.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Angel Yeast analysts - going out to 2026, and you can see them free on our platform here.

You should always think about risks though. Case in point, we've spotted 1 warning sign for Angel Yeast you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment